Sarepta Therapeutics Stock
€113.85
Your prediction
Sarepta Therapeutics Stock
Pros and Cons of Sarepta Therapeutics in the next few years
Pros
Cons
Performance of Sarepta Therapeutics vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Sarepta Therapeutics | 2.130% | 1.200% | -9.929% | 3.312% | 28.673% | 55.831% | 52.003% |
Incyte Corp. | -0.630% | 2.685% | 1.797% | 3.843% | 3.807% | -8.993% | -20.081% |
Regeneron Pharmaceuticals Inc. | -1.160% | -1.489% | -4.382% | 31.474% | 28.589% | 87.546% | 281.866% |
Exact Sciences | -2.800% | 6.170% | 18.823% | -8.507% | -8.347% | -29.962% | -33.393% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.The financials of Sarepta Therapeutics, traded under the symbol AVII, reflect a complex picture shaped by its positioning in the Biotechnology and Medical Research sector. The company has been heavily investing in research and development, which is crucial in this industry. However, the resulting financial statements indicate significant losses, raising queries about its future performance and viability. While the potential for groundbreaking advancements in treatment options exists, investors must weigh the current financial challenges against future possibilities carefully.
Market Capitalization: With a market capitalization of approximately $12.9 billion, Sarepta has a robust presence in the biotech sector. This positioning facilitates investment opportunities and potential market confidence, reflecting the belief in its future innovations.
Revenue Growth: Revenues for Sarepta totaled about $1.4 billion in the most recent twelve months (TTM). This suggests that the company has viable product lines, delivering growth opportunities despite the ongoing losses.
Comments
News
This Early-Stage Biotech Stock Is Up 400% — Should You Buy Now?
Avidity Biosciences (NASDAQ: RNA) is a biopharmaceutical stock focusing on RNA therapeutics. The company’s stock is up around 400% so far in 2024.
However, even with this massive appreciation
Sarepta Therapeutics (SRPT) Q2 2024 Earnings Call Transcript
Sarepta Therapeutics (NASDAQ: SRPT)Q2 2024 Earnings CallAug 07, 2024, 4:30 p.m. ET
Operator
Source Fool.com
After a Big Win, Is Sarepta Therapeutics Stock a Buy?
On June 20, the Food and Drug Administration (FDA) gave Sarepta Therapeutics (NASDAQ: SRPT) exactly what it wanted. The agency upgraded the status of its gene therapy for Duchenne muscular dystrophy